by Janncike Kristoffersen | Jan 21, 2025
The Clinical Research Unit at Oslo University Hospital was selected as the sole centre worldwide to conduct a “first-in-human” study of an entirely new MRI contrast agent. Much of the preclinical development were carried out in Norway by GE HealthCare...
by Janncike Kristoffersen | Jan 6, 2025
2024 ended on a positive note. Zelluna and Ultimovacs merged in an exciting collaboration to advance their precision cell therapies into clinical trials. This merger was strengthened by over NOK 50 million in fresh capital from private investors, including Inven2....
by Janncike Kristoffersen | Jan 5, 2024
Inven2 is grateful to everyone who has contributed to building business and helping patients through new inventions, clarification, clinical studies, and commercial results. When someone is willing to pay for products, services, and values created when knowledge is...
by Janncike Kristoffersen | Jan 16, 2023
In April 2021, the Dutch company CellPoint in-licensed a CD37 CAR from Inven2. It is a kind of cell therapy for treating blood cancer developed by Else Marit Inderberg and Sébastien Wälchli’s research group at the Radium Hospital, Oslo University Hospital. ‘Clinical...
by Elisabeth Kirkeng Andersen | Sep 25, 2020
Inven2 handles agreements for clinical studies on behalf of the Cancer Clinic at Oslo University Hospital for most Norwegian companies that develop cancer treatments. “This is an important contribution to the Norwegian health industry and shows that we are competing...
by Elisabeth Kirkeng Andersen | Aug 16, 2020
Inven2 is 10 years in 2020. ‘I’m proud of what we have achieved over these ten years. I’m particularly proud of the fact that we have contributed to ploughing NOK 500 million back into new research, innovation and to inventors,’ says Ole Kristian Hjelstuen, CEO of...
